Thursday - April 16, 2026
Bayer USA: Statement on New England Journal of Medicine Publication of Phase III OCEANIC-STROKE Study Evaluating Asundexian
April 16, 2026
WHIPPANY, New Jersey, April 16 (TNSjou) -- Bayer USA, an enterprise with core competencies in the life science fields of health care and nutrition, issued the following news on April 15, 2026:

* * *

Statement on New England Journal of Medicine Publication of Phase III OCEANIC-STROKE Study Evaluating Asundexian

Today, the New England Journal of Medicine published the full results from the global, pivotal Phase III OCEANIC-STROKE study. The study evaluated th . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products